Conditions:   Advanced Non-Small Cell Lung Cancer;   Metastatic Non-Small Cell Lung Cancer
Interventions:   Drug: MRTX849 Monotherapy;   Drug: MRTX849 in Combination with Pembrolizumab
Sponsor:   Mirati Therapeutics Inc.
Recruiting